# Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

> **NCT06107413** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 280 (estimated)

## Conditions studied

- Unresectable Metastatic Colorectal Cancer

## Interventions

- **DRUG:** ABBV-400
- **DRUG:** Bevacizumab
- **DRUG:** Folinic Acid
- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT06107413
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06107413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06107413, "Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06107413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*